載入中
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
最新資料
US$25.70
+US$1.10 · +4.47%
盤中時間採用ET。市場資料可能有所延遲。
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
盤中時間採用ET。市場資料可能有所延遲。
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$59.50
上漲空間 131.52%| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2013年11月4日 | US$0.225Quarterly | 2013年11月6日 | 2013年12月2日 |
股息 | 2013年8月12日 | US$0.225Quarterly | 2013年8月14日 | 2013年9月3日 |
股息 | 2013年5月6日 | US$0.225Quarterly | 2013年5月8日 | 2013年6月3日 |
股息 | 2013年2月4日 | US$0.225Quarterly | 2013年2月6日 | 2013年3月1日 |
股息 | 2012年2月6日 | US$0.21Quarterly | — | 2012年3月1日 |
除息 2013年11月4日
US$0.225
Quarterly
2013年11月6日登記 · 支付日 2013年12月2日
除息 2013年8月12日
US$0.225
Quarterly
2013年8月14日登記 · 支付日 2013年9月3日
除息 2013年5月6日
US$0.225
Quarterly
2013年5月8日登記 · 支付日 2013年6月3日
除息 2013年2月4日
US$0.225
Quarterly
2013年2月6日登記 · 支付日 2013年3月1日
除息 2012年2月6日
US$0.21
Quarterly
支付日 2012年3月1日
報告持有此股票曝險的交易所交易基金。
ARK Innovation ETFARKK1.56億2.27%55.62億 USD0.75%US$89.62+2.31%
Vanguard Morningstar Total Stock Market ETFVTI9659.53萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI8579.5萬0.87%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Small-Cap ETFVB6961.99萬0.04%1853億 USD0.03%US$289.48+0.64%
ARK Genomic Revolution ETFARKG6634.51萬3.24%15.57億 USD0.75%US$51.30+4.08%
iShares Russell 2000 ETFIWM6426.34萬0.08%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK4010.45萬0.09%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF3408.01萬0.03%954億 USD0.05%US$235+0.80%ARK Innovation ETFARKKVanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
